Byron Jones
#182,767
Most Influential Person Now
Researcher
Byron Jones's AcademicInfluence.com Rankings
Byron Jonesengineering Degrees
Engineering
#8595
World Rank
#10169
Historical Rank
Electrical Engineering
#2690
World Rank
#2829
Historical Rank
Byron Jonescomputer-science Degrees
Computer Science
#11635
World Rank
#12354
Historical Rank
Machine Learning
#5347
World Rank
#5415
Historical Rank
Artificial Intelligence
#5766
World Rank
#5851
Historical Rank
Database
#8701
World Rank
#9126
Historical Rank
Download Badge
Engineering Computer Science
Byron Jones's Degrees
- PhD Computer Science Stanford University
- Masters Electrical Engineering University of California, Berkeley
- Bachelors Computer Engineering University of California, Berkeley
Similar Degrees You Can Earn
Why Is Byron Jones Influential?
(Suggest an Edit or Addition)Byron Jones's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Design and Analysis of Cross-Over Trials (1989) (1221)
- Trials to assess equivalence: the importance of rigorous methods (1996) (1012)
- Design and Analysis of Cross-Over Trials, Second Edition (2003) (254)
- Choosing among generalized linear models applied to medical data. (1998) (186)
- The analysis of data from 2 x 2 cross-over trials with baseline measurements. (1987) (69)
- Generalized Nonlinear Models for Pharmacokinetic Data (2000) (64)
- Statistical approaches for conducting network meta‐analysis in drug development (2011) (62)
- Modelling binary data from a three-period cross-over trial. (1987) (55)
- The design of multicentre trials (2005) (54)
- A Log‐Linear Model for Binary Cross‐Over Data (1987) (51)
- A comparison of various estimators of a treatment difference for a multi-centre clinical trial. (1998) (49)
- Kullback–Leibler divergence for evaluating bioequivalence (2003) (42)
- Modelling and design of cross-over trials. (1996) (41)
- Alternative approaches to the analysis of binary and categorical repeated measurements. (1992) (39)
- Modeling and Interpreting QTc Prolongation in Clinical Pharmacology Studies (2005) (36)
- Batch‐to‐batch pharmacokinetic variability confounds current bioequivalence regulations: A dry powder inhaler randomized clinical trial (2016) (33)
- Bioequivalence and statistics in clinical pharmacology (2005) (30)
- A review of uniform cross-over designs (2008) (28)
- Design and Analysis of Cross-Over Trails. (1991) (27)
- Some statistical issues in modelling pharmacokinetic data (2001) (27)
- The case for cross-over trials in phase III. (1995) (26)
- The analysis of categorical data from cross-over trials using a latent variable model. (1991) (23)
- The analysis of binary and categorical data from crossover trials (1994) (22)
- Fitting Emax models to clinical trial dose–response data (2011) (21)
- Statistical issues with the analysis of nonrandomized studies in comparative effectiveness research. (2011) (21)
- An update on the clinical evidence that supports biosimilar approvals in Europe (2018) (20)
- Clinical trials for authorized biosimilars in the European Union: a systematic review (2016) (20)
- Between‐Batch Pharmacokinetic Variability Inflates Type I Error Rate in Conventional Bioequivalence Trials: A Randomized Advair Diskus Clinical Trial (2016) (18)
- Simple models for repeated ordinal responses with an application to a seasonal rhinitis clinical trial. (1997) (16)
- Properties of the weighted log‐rank test in the design of confirmatory studies with delayed effects (2018) (16)
- ESTIMATION OF THE COMBINED RESPONSE TO TREATMENT IN MULTICENTER TRIALS (2001) (14)
- The construction of nearly balanced and nearly strongly balanced uniform cross-over designs (2006) (14)
- D-efficient window experimental designs (2008) (13)
- Controlling the type I error rate in two‐stage sequential adaptive designs when testing for average bioequivalence (2018) (13)
- Bioequivalence and the pharmaceutical industry (2002) (12)
- Modeling the covariance structure in pharmacokinetic crossover trials. (1999) (12)
- Viewpoint: observations on scaled average bioequivalence (2012) (11)
- Incorporating historical information in biosimilar trials: Challenges and a hybrid Bayesian‐frequentist approach (2018) (10)
- Model-Based Bayesian Adaptive Dose-Finding Designs for a Phase II Trial (2011) (9)
- Examination of Data, Analytical Issues and Proposed Methods for Conducting Comparative Effectiveness Research Using "Real-World Data" (2015) (9)
- The Assessment of Quality Attributes for Biosimilars: a Statistical Perspective on Current Practice and a Proposal (2018) (9)
- MODELING PHARMACOKINETIC DATA USING HEAVY-TAILED MULTIVARIATE DISTRIBUTIONS (2000) (8)
- Treatment-patient interactions for diagnostics of cross-over trials. (1997) (8)
- The cross‐over trial: a subtle knife (2008) (7)
- Simultaneous modelling of flosequinan and its metabolite (2000) (6)
- Simulation assessments of statistical aspects of bioequivalence in the pharmaceutical industry (2004) (6)
- Sample Size for Multiple Hypothesis Testing in Biosimilar Development (2018) (6)
- Analysis of cross-over trials for duration data. (1996) (6)
- Longitudinal assessment of the impact of multiple switches between a biosimilar and its reference product on efficacy parameters (2018) (6)
- Estimation of the Treatment Difference in Multicenter Trials (2004) (5)
- Integrated Data Analysis for Assessing Treatment Effect through Combining Information from All Sources (2017) (5)
- A model for cross-over trials evaluating therapeutic preferences. (1996) (5)
- A brief review of Phase 1 and Clinical Pharmacology statistics in clinical drug development (2007) (5)
- Construction of A-Optimum Cross-Over Designs (1995) (5)
- Lessons from meta‐analyses of randomized clinical trials for analysis of distributed networks of observational databases (2018) (5)
- THE DESIGN AND ANALYSIS OF MULTICENTRE TRIALS IN THE RANDOM EFFECTS SETTING (2002) (4)
- A proposal for a new PhD level curriculum on quantitative methods for drug development (2018) (4)
- The 2 × 2 cross-over trial (2014) (3)
- Cross‐over trials in practice: tales of the unexpected (2008) (3)
- Optimizing dose regimens and fixed dose combination ratios in clinical trials (2016) (3)
- Statistical methodology for highly variable compounds: A novel design approach for the ofatumumab Phase 2 bioequivalence study (2022) (3)
- Batch Selection via In Vitro/In Vivo Correlation in Pharmacokinetic Bioequivalence Testing (2021) (3)
- Analysis of discrete data (2014) (2)
- Re: randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido: north central cancer treatment group protocol N02C3. (2008) (2)
- Multi-Center Clinical Trials with Random Enrollment: Theoretical Approximations (2005) (2)
- Analysis of Binary Data@@@Design and Analysis of Cross-Over Trials (1991) (1)
- Dose optimisation with simultaneous pharmacokinetic estimation in adaptive clinical trials (2019) (1)
- Clinical Pharmacology Safety Studies (2005) (1)
- Dynamic modelling of a challenge‐escalation cross‐over study of treatment of capsaicin‐induced coughing (2002) (1)
- Testing for Average Bioequivalence (2005) (1)
- Response to comments on “Properties of the weighted log‐rank test in the design of confirmatory studies with delayed effects” by José L. Jiménez, Viktoriya Stalbovskaya and Byron Jones, Pharmaceutical Statistics, 2019; 18:287‐303, DOI: 10.1002/pst.1923 (2020) (1)
- II. Simulation and Retrospective Assessment of Performance of the Proposed FDA metric and the Kullback-Leibler Divergence in Individual Bioequivalence Assessment (2001) (1)
- Testing Procedures for Claiming Success on at Least k Out of m Hypotheses with an Application to Biosimilar Development (2021) (1)
- Bioequivalence: A Review of Study Design and Statistical Analysis for Orally Administered Products (2006) (1)
- Case study: Unblinded sample size re-estimation in a bioequivalence study that has a group sequential design (2014) (0)
- Generating the Right Evidence at the Right Time: Principles of a New Class of Flexible Augmented Clinical Trial Designs (2022) (0)
- SAS code for assessing ABE, IBE and PBE in replicate cross-over trials (2003) (0)
- Analysis of Continuous Data (2003) (0)
- Case study: Various methods for an unblinded sample size re-estimation in a bioequivalence study (2014) (0)
- Dealing with Unexpected BE Challenges (2005) (0)
- Crossing over to cross‐over trials (2009) (0)
- Designing cross-over trials for three or more treatments (2014) (0)
- Properties of the weighted log-rank test under delayed effects assumption in the design of confirmatory studies with delayed effects (2018) (0)
- Response to the letter to the editor regarding our article ‘statistical methodology for highly variable compounds: A novel design approach for the ofatumumab phase 2 bioequivalence study’ https://doi.org/10.1002/pst.2233 (2022) (0)
- Deriving Approximations in a Random Effects Model for Multicenter Clinical Trials with Binary Response (2007) (0)
- : Higher-order designs for two treatments (2014) (0)
- Case study: Conditional power (2014) (0)
- History and Regulation of Bioequivalence (2017) (0)
- Dose Ranging Crossover Designs (2014) (0)
- Cross-over Trials (2021) (0)
- Case study: Phase I dose–response noninferiority trial (2014) (0)
- Least squares estimation (2003) (0)
- 7 Example 5.1: INNOVO trial: dose–response study (2014) (0)
- 'HIILFLHQW:LQGRZ'HVLJQVIRU1RQ/LQHDU0RGHOV (2007) (0)
- Case study: Proof of concept trial with sample size re-estimation (2014) (0)
- Biosimilar Drug Development (2020) (0)
- Analysis of Categorical Data (2003) (0)
- Response to comments on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharm Stat 17(5):593‐606, Sep/Oct 2018., DOI: https://doi.org/10.1002/pst.1873 (2019) (0)
- Case study: Choosing a dose–response model (2014) (0)
- Adaptive designs for phase II cross-over dose-finding trials using Bayesian model averaging (2015) (0)
- A quasilinear regression model for cross-over trials (1994) (0)
- Clinical Pharmacology Efficacy Studies (2017) (0)
- The Future and Recent Past of BE Testing (2005) (0)
- BE Studies with More Than Two Periods (2005) (0)
- D-efficient Window Designs for Non-Linear Models (2007) (0)
- Optimal cross-over designs for nonlinear mixed models using a first-order expansion (2009) (0)
- Drug Development and Clinical Pharmacology (2005) (0)
- Model based dose personalization in clinical trials (2021) (0)
- Case study: Blinded sample size re-estimation in a bioequivalence study (2014) (0)
- Table of Contents Examination of Data , Analytical Issues and Proposed Methods for Conducting Comparative Effectiveness Research Using “ Real-World Data ” (2011) (0)
- 31. Dose Ranging Crossover Designs (2014) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Byron Jones?
Byron Jones is affiliated with the following schools:
